SCHEMBL2415253

SCHEMBL2415253

Cc1ccc(N(CCc2csc(SC(C)(C)C(=O)O)n2)Cc2cnn(-c3ccccc3)c2)nc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 2/20 0.35
BRPF1 P55201 2/20 0.35
MAPT P10636 5/20 0.33
LMNA P02545 4/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 3/20 0.33
KDM4E B2RXH2 2/20 0.33
RAB9A P51151 2/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
NR4A1 P22736 1/20 0.33
MPI P34949 1/20 0.33
RECQL P46063 1/20 0.33
ESR2 Q92731 1/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.31
CYP2C9 P11712 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
SMN1; SMN2 Q16637 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2415049 0.91 MEN1 (0.34) ERCC5BRPF1MAPTLMNAALDH1A1
SCHEMBL2413214 0.88 BRPF1 (0.36) ERCC5BRPF1MAPTLMNAALDH1A1
SCHEMBL12273248 0.87 MAPT (0.33) ERCC5BRPF1MAPTLMNAALDH1A1
SCHEMBL2408022 0.87 MEN1 (0.34) ERCC5BRPF1MAPTLMNAALDH1A1
SCHEMBL2412096 0.86 BRPF1 (0.33) ERCC5BRPF1MAPTLMNAALDH1A1
Hydrochloric Acid SCHEMBL2413850 0.86 MAPT (0.32) ERCC5BRPF1MAPTLMNAALDH1A1
SCHEMBL2415594 0.86 BRPF1 (0.33) ERCC5BRPF1MAPTLMNAALDH1A1
SCHEMBL12274068 0.85 ERCC5 (0.34) ERCC5
SCHEMBL2412677 0.85 PPARG (0.33) ERCC5BRPF1MAPTLMNAALDH1A1
SCHEMBL12273122 0.85 BRPF1 (0.35) ERCC5BRPF1MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG ERCC5 4833/4885BRPF1 1560/4885MAPT 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.